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Abstract 
Background: Thyrotoxicosis is a common endocrine disorder 
worldwide with a female predominance. Graves disease is reported as the 
commonest cause of thyrotoxicosis by various authors in the Africa region. 
Aims and Objectives: The study evaluated patient characteristics, clinical and 
laboratory profile, co-morbidities, treatment modalities, response to therapy, 
side effects of anti-thyroid medications, treatment outcome and complications 
of the disease in patients with thyrotoxicosis. Materials and methods: This 
study was retrospective and observational. The records of patients diagnosed 
with overt thyrotoxicosis seen in the Endocrine unit (2013-2017) were pulled 
and relevant data compiled. Data was analyzed using SPSS V 21. Results: A 
total of 172 cases were studied; 33 males and 132 females (ratio 1:4). They 
were aged 18-70; 40.2 ±12.5 years. Graves Disease constituted 79 % 0f cases 
and toxic multinodular goiter made up 18%. Seven cases of Marine Lenhart 
syndrome were identified. Graves orbitopathy occurred in 54%, but was mild. 
All but 6 patients received anti-thyroid medication as initial therapy mainly 
carbimazole (90%). About 6% had thyroidectomy. Treatment default was high 
(52%), while 15% remitted and 19% relapsed. Total duration of illness was 1-
380, 40.7 ± 52.6 months. Drug rash occurred in 5% and cholestatic hepatitis 
in 1.8%. Hypertension coexisted in 35%. Six pregnancies were recorded, four 
of which ended in miscarriages, two of which had thyroid storm. Heart disease 
complicated the disease in 36%. Conclusion: Thyrotoxicosis is a common 
clinical condition. Treatment with carbimazole is effective. However the 
treatment default rate was very high. Coexisting hypertension and pronlonged 
period of untreated disease exposed patients to a high burden of heart disease. 
Patient education and introduction of radioablation therapy will mitigate these 
challenges. 
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Introduction 
Throtoxicosis is a common endocrine disorder worldwide. By 
definition, thyrotoxicosis refers to the clinical syndrome due to inappropriately 
raised circulating levels of thyroid hormones while hyperthyroidism implies 
increased synthesis and release of thyroid hormones by an overactive thyroid 
gland (Leo et al 2016). In general, the incidence of hyperthyroidism 
corresponds to population iodine nutrition. Various prevalence rates have been 
reported for hyperthyroidism in the general population in iodine sufficient 
areas of the world; 1-3% by Frankylen et al (2012) and 0.2% to 1.3% by 
Hollowell et al (2002). Higher rates of hyperthyroidism recorded in iodine 
deficient populations were ascribed to the excess of nodular thyroid disease in 
elderly patients (Laurberg et al 2006). Figures for the epidemiology of thyroid 
dysfunction in Africa are scarce due to absence of comprehensive population-
based studies (Taylor et al 2018). Long-term variations in iodine intake do not 
influence the risk of disease; however rapid repletion especially in regions of 
moderate-severe iodine deficiency increases the incidence of overt 
hyperthyroidism from toxic adenoma, toxic multinodular goiter, and Graves’ 
disease (Laurberg 2006). This was the case following successful universal salt 
iodization (USI) programs in Congo, (Bourdoux 1996) Zimbabwe (Todd et al 
1995) and Ghana (Sarfo-Kantanka et al 2017). Prior to 1993, Iodine 
Deficiency Disorders (IDD) was recognized as a public health problem in 
Nigeria. In 1994, the program of Universal Salt Iodization (USI) came into 
force and by 2005, Nigeria was certified as USI compliant (SCN News 2007). 
It is to be expected that the profile of thyroid diseases should shift from that 
of iodine deficient to iodine sufficient.  Graves disease has been reported as 
the commonest cause of thyrotoxicosis by various authors in the Africa region 
(Sarfo-Kantanka et al 2017, Ogbera et al 2011).  
  
Aims and Objectives 
The study evaluated the demographic socioeconomic, clinical and 
laboratory profile and co-morbidities in patients with thyrotoxicosis attending 
our endocrine clinic. It also studied modalities of treatment, response to 
therapy and the side effects of anti-thyroid medications, treatment outcome 
and complications of the disease. 
 
 Materials and methods 
This was a retrospective observational study. The records of patients 
diagnosed with overt thyrotoxicosis seen in the Endocrine unit of the 
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University of Nigeria teaching Hospital (UNTH), Enugu, Nigeria over a 5 year 
period (2013-2017) were pulled and evaluated. Relevant data were compiled 
including patient demographics (age, gender, highest educational level 
attained, parity and occupation), presentation and clinical features, 
biochemical features (TSH, fT4, fT3, TRAb and TPO, FBC, serum urea and 
creatinine levels), treatment method, adverse drug reactions, duration of 
disease from inception, duration of treatment, disease status and treatment 
outcome. In addition, patients were assessed for co-morbidities and 
complications of therapy. Thyrotoxicosis was diagnosed based on suggestive 
clinical features in the presence of a suppressed TSH (<0.01 µU/mL) and 
elevated fT4. Thyroid autoantibodies were requested for confirmation of cases 
of autoimmunity due to Graves Disease. Thyroid profile and auto-antibody 
results prior to starting medical therapy were used for analysis. Treatment 
status on intake was classified as naïve (never received ATDs), previously 
treated (had received ATDs in the past) or ongoing (was on ATDs at intake). 
Biochemical severity of the thyrotoxicosis was assessed using free fT4 levels.  
 
Treatment method 
Only two methods of treatment were available; medical (ATD) and 
surgery (thyroidectomy). Carbimazole was the main and preferred ATD being 
the only drug readily available. All patients received carbimazole. 
Propylthioracil was used only in pregnancy or where carbimazole was not 
tolerated. The titration method was used starting with initial doses of 30-
60mg/day and the dose tapered as the clinical features and biochemistry 
improved. Since 2015, the block and replace protocol was adopted to contain 
the arbitrary changes in ATD doses and chaotic thyroid function profile and 
therefore streamline the treatment algorithm. This problem arose because 
patients could not do their thyroid function tests as frequently and 
expeditiously as required. In this regime, Carbimazole was given at a steady 
dose of 30 mg daily with l-throxine 50-100 mg daily added when fT4 level 
returned to normal (usually at 3 months). Treatment was discontinued after 18 
months of ATD in those with controlled disease.  They were then followed 
with thyroid function tests at one month and 3 monthly thereafter.  The 
preferred beta blocker was propranolol which was used in all patients except 
where contraindicated. In such cases, atenolol was substituted. Patients who 
preferred surgery and those with nodular disease were referred to the surgical 
services. Surgery consisted of partial or total thyroidectomy. 
 
Treatment outcome 
The outcome of initial medical treatment was determined from 
biochemical response (fT4 and TSH) and clinical assessment and recorded as 
follows:  
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1. Ongoing and controlled disease: normalization of biochemistry whilst on 
ATDs  
2. Ongoing and uncontrolled disease: persistent symptoms or abnormal 
biochemistry despite ATDs  
3. Disease remission: patients whose disease was controlled with ATDs and 
where control was maintained for at least a month after withdrawal of 
medical treatment or patients who remitted after thyroidectomy. 
4. Defaulted: patients who did not complete the treatment schedule before 
discontinuing hospital attendance. 
5. Relapsed: patients previously remitted or returned after defaulting 
6. Unknown: where data or response were not available 
 
Patients who relapsed after initial remission with ATDs or 
thyroidectomy were re-started on ATDs. 
Data was analyzed using SPSS v 21 (SPSS, Inc, Chicago, IL, USA). 
Continuous variables were summarized using means and standard deviations. 
Categorical data was summarized using frequency tables and percentages. The 
relationship between variables was explored using 2 × 2 contingency tables to 
determine Chi squares and associated p-values. A p-value of <0.05 was 
considered statistically significant. 
 
Result 
Demographics  
A total of 172 cases were studied; 33 males and 132 females (ratio 1:4). 
Table 1 and Figure 1 present the basic data on the patients. The ages of males 
and females were comparative (p = 0.332). Their diet consisted of local 
staples. Drinking water came from rivers, streams, boreholes, tap, sachet and 
bottled water. Family history of thyroid disease was present in 12%, affecting 
primarily first degree relatives. All patients used iodized salt.  None of the 
patients was on lithium or amiodarone. Alcohol and tobacco use was very 
insignificant. 
Table 1, Patient demographics 
Total, 172 Male, 33 
 Females, 132 
Age (years) 18-70; 40..2 ±12.5 
  M = 18-67; 41.6 ± 14.2 
 F = 19-70; 39.9.0 ± 11.7 
Variable n % 
Education n=137   
Primary 22 20.5 
Secondary 38 38.5 
Tertiary 96 61.5 
Marital status 
Single 54 31.4 
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Married 111 64.5 
Widowed 7 4.0 
* Parity 0-10 (4.0 ± 2.5)  
Occupation  
† Tech./Ass Prof 26 15.1 
‡ Cler/Supp Workers 26 15.1 
§ Craft Rel/Trade Workers 43 25.0 
Students 36 20.9 
Others 41 23.9 
Family and social history 
|| Family hx goiter 21 12.2 
Family hx thyrotoxicosis 2 1.2 
Family hx vitiligo 2 1.2 
Use iodized salt 169 98.3 
Use  extra iodized salt 3 1.7 
Herbals 17 10.3 
Supplements 23 13.9 
Contraceptive use 1 0.6 
Alcohol 2 1.2 
Tobacco  2 1.2 
* Females only, † Technical and Associate professionals, ‡ Clerical and Support workers, § 
Craft Related and Trade workers, || hx-history  
 
Figure 1, Age distribution of patients 
 
Clinical presentation 
The details of the presenting features are in Table 2 and 3 and Figure 
2. The top ten symptoms were weight loss, heat intolerance, palpitations, 
hyper-defecation, excess sweating, goiter, increased appetite, bulging eyes, 
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fatigue, and nervousness. The frequencies would have been higher if all 
patients were treatment naïve. The stool count was 2-20/day (5± 3, median 4).  
 BMI could be assessed in only a third of the subjects where records were 
available. Tachycardia was recorded in 100% in all treatment naïve subjects. 
Of the ten subjects with irregularly, irregular pulse, one was male aged 49 
years and the rest were female aged 35-68 years (50.3 ± 10.4, median 51). 
Other common physical signs were goiter, eye signs, fine finger tremor, warm 
and moist palms. Pretibeal myxedema was observed in 4.1% and was of the 
diffuse and mixed (diffuse with nodules or plaque) types. No case of thyroid 
acropachy was recorded. Grade 0 goiters were observed in subjects on current 
or previous ATDs. Eye signs of Graves orbitopathy consisted of proptosis, 
periorbital edema and lid retraction. They were mild and regressed with ATD 
treatment except in two persons. 
Table 2, Presenting symptoms 
Variable n % 
Treatment Status at intake 
Naïve 98 59.4 
Current 41 24.8 
Previous 26 15.8 
Symptoms (n=172)   
Weight loss 148 86 
Heat intolerance 141 82 
Palpitations 140 81.4 
Hyperdefecation 128 74.4 
Stool count 2-20; 5 ± 3  
Appetite changes 117 70.9 
Same 30 18.2 
Increased 101 61.2 
Decreased 16 9.7 
Excess sweating 116 67.4 
Goiter 109 63.4 
Hand tremor 107 62.2 
Bulging eyes 94 54.7 
Grittiness eyes 41` 23.8 
Visual impairment 10 5.8 
Fatigue 94 54.7 
Nervousness 89 51.7 
Insomnia 82 47.7 
Shortness of breath 73 42.4 
* Menstrual changes (n=132) 62 47 
Hypomenorrhea 32 24 
Amenorrhea 24 18 
Menorrhagia 6 4.5 
Postmenoupausal 24 18 
Leg swelling 40 23.3 
Muscle aches 37 21.5 
Polydipsia 35 21.2 
PMW 32 18.6 
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Polyuria 31 18 
Cough 28 16.3 
Mood swings 26 15.1 
Orthopnea 21 12.2 
PND 19 11.0 
Skin hyperpigmentation 20 11.6 
Hair loss 18 10.5 
Pruritus 14 8.1 
Persistent headache 11 6.4 
Infertility 10 5.8 
Vitiligo 4 2.3 
Erectile dysfunction 3 1.7 
Weight gain 2 1.2 
Psychosis 2 1.2 
Symptom duration before 
presentation 
1-84; 18.6 ± 18.5, median 12 (months) 
* Females only 
 
Figure 2, Frequency of symptoms 
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Table 3, Physical and laboratory findings (n-172) 
Variable n % 
Appearance   
Healthy calm 99 60 
Anxious 47 28.5 
Wasted 39 23.6 
Acutely ill 4 2.4 
Obese  2 1.2 
Apathetic 2 1.2 
BMI 15.6-33.2; 24.4 ± 4.2 median 23.9 
Pulse rate 92-148; 113 ±12.7, median 111 
Irregular pulse 10 6.9 
Systolic blood pressure 80-190; 131 ± 20, median 130 
Diastolic blood pressure 40-120; 77 ± 13, median 80 
Goiter 147 89.1 
Grade 2 135 78.5 
Grade 1 18 10.5 
Grade 0 19 11 
Diffuse 127 73.8 
Multinodular 24 14 
Single nodule 2 1.2 
Tender 4 2.4 
Eye signs 102 59.3 
Proptosis 92 53.5 
Symmetrical 77 44.8 
Asymmetrical 11 6.4 
Unilateral 4 2.3 
Chemosis 2 1.2 
Ophthalmoplegia 4 2.3 
Lid retraction 95 55.2 
Lid lag 22 12.8 
Sight loss 1 0.6 
Fine finger tremor 95 55.2 
Warm palms 73 42.4 
Moist palms 38 22.1 
Proximal myopathy 18 10.9 
Pedal edema 17 10.3 
Onycholysis 13 7.6 
Pretibial myxedema 7 4.1 
Vitiligo 4 2.3 
Illness Severity   
Mild 53 42.1 
Moderate 67 53.2 
Severe 6 3.5 
Laboratory data 
Hemoglobin   6.7-16.4; 11.9 ±1.6 g/dl 
WBC 2.9-14; 5.7 ± 1.8 x 109/l 
Urea 1.9-9.3; 4.1 ±1.5 mmol/l 
Creatinine 27-215; 967 ± 27.5µmol/l 
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Etiologic Diagnosis 
The etiologic causes of the thyrotoxicosis are presented in Table 4. GD 
was diagnosed in 79%, Toxic multinodular goiter (TMNG or Plummer’s 
Disease) in 16.8% and Toxic adenoma (TA) in 1.8%. There were single cases 
of thyroiditis and secondary hyperthyroidism (all females). There was no 
significant difference in the etiologic factors between males and females (p = 
0.910). 
Table 4, Etiologic diagnosis and illness severity (n=172) 
Etiologic Diagnosis 
Variable n % 
GD 135 78.4 
Males 29 16.8 
Females 107 62.3 
†MLS (females) 7 4.0 
TMNG 31 17.6  
Males 5 2.9 
Females 26 15.1 
Toxic Adenoma 3 1.8 
Male 1 0.6 
Female 2 1.2 
Thyroiditis 1 0.6 
2 Hyperthyroidism 1 0.6 
Illness severity   
Mild 51 41.1 
Moderate 57 54.0 
Severe 6 3.5 
 
Illness severity 
Illness severity was classified using fT4 cut off values according to 
Iglesias et al (2009) into Mild (fT4 1.8-3.9 ng/dl or 23-50 pmol/l); Moderate 
(3.8-50 ng/dl or 50-99 pmol/l) and Severe Hyperthyroidism (> 3.9 ng/dl or > 
100 pmol/l). This classification was only possible in subjects where fT4 was 
measured and this is shown in Table 4.  Illness severity was comparative 
between males and females (p = 0.214). 
 
 Thyroid auto-antibodies 
The level of thyroid autoantibody testing was very low, but has picked 
up in later years. Testing was selective targeting subjects with Graves Disease 
features and was possible only in those who could afford the test. TPO Ab 
were positive in all 34 (19.8%) tested.   (TRAb) in 32 (18.6%) tested. Seven 
cases of Graves Disease with nodular goiter MLS were picked us a result of 
such testing; all females aged 33-56 (41.1 ± 7.7) years. 
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Treatment and medication adherence 
All subjects were offered ATD drugs except for 6 who defaulted before 
treatment could be started and the lone patient with thyroiditis (Table 5). In 
all, 163 (90.1%) received ATDs only, while 10 (6.1%) eventually underwent 
thyroidectomy. Carbimazole was commonly used (88.7%). Treatment resulted 
in rapid regression of symptoms (4-12 weeks). The total treatment duration on 
ATDs was 1-65 months (16.0 ± 15.2, median 12 months). Medication 
adherence was assessed as good in only 45%. Some subjects used their 
medication intermittently and in 16%, the status was unknown. The unknown 
cases were early defaulters where no meaningful assessment could be made. 
Adverse drug events with carbimazole resulted in pruritic, papular rash in 
7.3% and hepatitis in 1.8%. The hepatitis was cholestatic. The events occurred 
within 3-12 weeks of commencement of therapy (Table 5). The skin reactions 
were controlled with antihistamines and a short course steroid therapy in one 
case. The hepatitis resolved spontaneously on drug withdrawal. 
Table 5, Disease management and outcome 
Treatment  
Antithyroid medication 164 95.3 
Carbimazol  154 89.5 
Propylthiouracil 10 5.8 
Symptom free (n=65) 4-12, 8.1 ± 3.0, median 4 weeks 
Treatment duration 1-65 (16.0 ±15.2) months, Median 12 months 
Medication adherence 
Good 77 44.8 
Poor 45 26.2 
Intermittent 27 15.7 
Unknown 27 16.4 
Complication ATD   
Rash 9 5.2 
Hepatitis 2 1.2 
Rash+hepatitis 1 0.6 
Latent period 3-12 weeks  
Final treatment modality 
Medical 156 90.1 
Surgical 10 5.8 
No treatment 6 3.5 
Disease status at assessment 
Controlled 98 57 
Uncontrolled 68 39.5 
No treatment  6 3.5 
Treatment status  
Ongoing 50 29.1 
Defaulted 89 51.7 
Remitted 26 15.1 
No treatment 6 3.5 
Died 1 0.6 
Relapses  24 14.0 
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Post-carbimazole 21 12.2 
Post-thyroidectomy 3 1.7 
No of relapses   
1 14 8.1 
2 8 4.7 
3 2 1.2 
Duration of illness 1-380, 40.7 ± 52.6 month 
 
Disease and treatment status  
As at the time of assessment, the disease was controlled in 57%, and 
uncontrolled in 39.5% of those treated (166). Of the 172 subjects, 52% had 
defaulted; treatment was ongoing in 29%, while 15% met the criteria for 
remission (Table 5). Remissions occurred in 10 who underwent thyroidectomy 
and in 14 on ATDs. There were 24 relapses in the series (3 post-thyroidectomy 
and 21 post-carbimazole). The relapses occurred once in 14 persons (including 
all previous thyroidectomies), twice in eight persons and three times in two 
cases. Relapses here refer to subjects who returned with the illness after an 
initial treatment episode whether or not they met the criteria for remission in 
that episode. 
 
 Co-existing conditions 
Hypertension was the commonest co-morbidity occurring in 35% of 
which 52% had prior knowledge of this condition (Table 6). The hypertension 
was systolic (>140/<90 mm Hg) in only 12 of the 60 (20%). Diabetes mellitus 
(DM) with or without hypertension was coexistent in 3.6%. Others conditions 
are in listed in Table 6. The lone asthmatic patient was also hypertensive. Six 
pregnancies occurred during the illness.  
 
Thyrotoxicosis associated complications 
Thyrotoxicosis was associated with heart disease in 36% and overt 
heart failure in 9%. Screening for heart disease was not routine; being 
undertaken in subjects who were hypertensive or had suggestive features of 
heart failure or were preparing for surgery. Diagnosis was based on presence 
of compatible signs on plain chest radiography, electrocardiography or 2D 
echocardiography (cardiomegaly, AF, left atrial abnormalities, LVH, systolic 
or diastolic dysfunction). The vast majority of GO was mild. Moderate-severe 
disease occurred in 2 (1.2%). One was a lady aged 56 years with asymmetric 
disease, eye pain, chemosis and excess lacrimation.  The other was a 64 years 
old man presenting solely with eye disease; proptosis, ophthalmoplegia, eye 
pain, chemosis, exposure keratitis, panophthalmitis and sight loss.  These were 
the only ones requiring intervention. Two subjects came down with stroke and 
new onset Type 2 diabetes mellitus occurred in one subject. Of the 6 
pregnancies that occurred during the illness, 4 ended in miscarriages and one 
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in preterm delivery of a live baby.  Thyroid storm occurred in 2 (1.2%) of 
subjects who were pregnant. All the pregnant women unilaterally withdrew 
ATDs without physician knowledge fearing for the health of their baby. One 
death occurred in a subject whose disease was partially controlled, but died 
suddenly at home. 
Table 6, Co-morbidities and complications 
Co-existent conditions 
Hypertension 60 34.9 
HPN + DM 3 1.7 
DM 3 1.7 
PUD 2 1.2 
*DUB/Fibroids 4 2.3 
Bronchial Asthma 1 0.6 
Pregnancies 6 3.5 
†CKD  1 0.6 
Illness complications  
Heart Disease 61 35.5 
Overt heart failure 15 8.7 
Moderate-severe GO 2 1.2 
Thyroid storm 2 1.2 
Miscarriages 4 2.4 
Preterm delivery 1 0.6 
CVA 2 1.2 
DM 1 0.6 
* Dysfunctionsl uterine bleeding  † chronic kidney disease 
 
Discussion  
Presentation  
Thyrotoxicosis remains a disease affecting predominantly women. The 
age and gender distribution is similar to what is obtained in many developed 
countries which are iodine sufficient (Weetman 2000, Brent 2008). This is to 
be expected since population iodine nutrition in Nigeria has become optimal. 
The age distribution was unimodal. 
The historical and examination findings are in keeping with the usual features 
of thyrotoxicosis found elsewhere; in the west, (Weetman 2000, Brent 2008, 
Smith et al 2016, DeGroot 2012),  India, (Sahay 2011) Iran (Othman et al 
2011) with local variations. Local researches have recorded similar findings 
including the series by Olurin as early as 1974 (Olurin 1974, Ogbera et al 
2007, Sarfo-Kantanka et al 2018, Ayandipo et al 2018). Though 57% of the 
patients had GO, only two required attention. Other authors reporting from the 
region had noted that the majority of patients with GO have mild ocular 
symptoms and require only minimal intervention. Chemosis, severe proptosis 
and ocular motility disorder were very rare. This has been related to the low 
prevalence of smoking in the disease population (Ogun et al 2016). The 
severity of thyroid eye disease has been linked to cigarette smoking (Åsvold 
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et al 2007). Six variants of pretibial myxedema have been described; nodular, 
plaque, diffuse, tumor, mixed (combination of other variants) and 
elephantiasis types (Lan et al 2016). Two cases in this study were diffuse while 
the rest were of the mixed type. Vitiligo has a well known association with 
autoimmune diseases thyroid included and was present in 4 cases (Nunes et al 
2011). 
 
Etiology 
Graves disease was the dominant cause of thyrotoxicosis in this report 
similar to other reports both local and global. It is possible that cases of 
thyroiditis with transient thyrotoxicosis may have resolved before patients 
could be referred to the Endocrine Clinic and therefore poorly represented in 
this report. One case of secondary hyperthyroidism due to thyrotrophin 
secreting pituitary adenoma was found and is awaiting surgery. Thyrotrophin 
secreting pituitary adenomas are notably rare (Beck-Peccoz 2000). The goiter 
in Graves disease is characteristically diffuse, but may not always be so. In the 
series by Bhargav (2014), the nature of the goiter can be nodular or atrophic. 
Goiter nodularity in Graves disease can also be due to simultaneous presence 
of toxic nodules; the Marine Lenhart Syndrome (Marine and Lenhart 1911, 
Charles 1973) Radioisotope scans may help in clarifying such cases. In this 
report, seven (4.0%) of such cases of multinodular goiter by ultrasound with 
elevated TRAb titers and proptosis were identified. 
 
 Treatment  
ATDs are preferred primary treatment for thyrotoxicosis in most 
countries other than North America. The initial dose of carbimazole is 15–30 
mg daily for mild hyperthyroidism and 20 –40 mg daily for moderate to severe 
disease. Block and replace and titration regimens are equally effective 
(Abraham 2010).  The block and replace regimen suited the local setting. ATD 
was very effective in controlling the disease as was documented in an earlier 
report from our center (Modebe 1992). The treatment default rate in this study 
was very high. This was also noted in the report by Olurin (1974) and Ogbera 
et al (2007). Adherence to long time therapies is problematic in this culture. 
Since ATDs were very effective, many patients considered themselves cured 
and left without reference to the physician. Work stoppages due to workers 
strike action are common in Nigeria and may last as long as four months; and 
occur at least once a year. During these periods, patients seek help elsewhere, 
usually private establishments and may never return. A number of the patients 
were students who returned to base or gained admission to universities and 
continued their treatment elsewhere. Similarly, patients requiring surgery may 
decide to do so in a private hospital of their choice and are lost to follow up. 
Moreover, there is no existing system for patient recall. All these factors have 
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direct bearing on figures for treatment and disease outcome as outlined in the 
study. No categorical statement could be made about the remission rate under 
these circumstances which was only 15%. An earlier study from the same 
center in the 1990s by Modebe (1992) yielded a remission rate of 61% on 
ATDs and a patient default rate of 32%.  Those with nodular goiter should 
proceed to surgery (total or near total thyroidectomy) as definitive treatment, 
but again quite a number could not be stabilized for surgery, cannot afford 
surgery or do not want surgery. Radioablation therapy would have been the 
most suitable alternative especially as the pharmaco-ecocomics is favorable 
(Ogunjobi et al 2015). However, both surgery and radioablation result in 
hypothyroidism requiring lifelong treatment with l-thyroxine. This in itself 
presents another major problem. Again, hypothyroidism presents with 
nondescript signs and symptoms and more difficult to recognize than 
hyperthyroidism. For those with recurrent Graves Disease, some recent studies 
have reported that compared with radioactive iodine or thyroidectomy, a 
second course of ATD or prolonged low dose ATD treatment led to prolonged 
remission while minimizing the risk of side effects (Azizi  et al 2005, Liu et al 
2015, Villagelin et al 2015). Long-term continuous treatment of 
hyperthyroidism with methimazole is reported as safe (Hussain et al 2017). 
These treatment modalities are viable alternatives for such cases. 
Identification of patients at high risk for relapse (male sex, large goiters, a high 
fT3, low TSH levels, high TRAb and smoking) will assist in counseling 
patients on the best treatment approach (Hussain et al 2017, Liu et al 2017). 
 
Adverse drug reaction 
About 5% of patients using ATDS will experience some drug related 
side effect most commonly a drug rash (Cooper 2005) Hepatotoxicity and 
agranulocytosis are uncommon. Cholestatic hepatitis occurred 1.8% of cases 
and resolved following drug withdrawal. Macula-papular rash and cholestatic 
hepatitis is typical of carbimazole induced drug reactions.  No case of 
agranulocytosis was encountered. 
 
Thyrotoxicosis, hypertension and heart disease 
Thyroid hormones have profound effects on the heart and vascular 
system. T3 effect on heart function is mediated by genomic and non-genomic 
pathways (Biondi 2012). Thyrotoxicosis is characterized by an increase in 
resting heart rate, blood volume, stroke volume, myocardial contractility, and 
ejection fraction. Cardiac dysfunction is manifested by left ventricular 
hypertrophy, heart rhythm disturbances, heart chamber dilation and heart 
failure, pulmonary hypertension, systolic and diastolic dysfunction (Vargas-
uricoechea et al 2017). It is estimated that the prevalence of hypertension with 
thyrotoxicosis is 20–30% (Prisant et al 2006). Thyrotoxicosis typically causes 
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isolated systolic hypertension. However, in this study only in 20% of cases 
was the hypertension systolic suggesting pre-existing diastolic hypertension. 
The large burden of cardiac disease seen in thyrotoxicosis in Africa has been 
noted by several authors (Ogbera et al 2007, Anakwue et al 2015). This was 
attributed to some genetic susceptibility. However, analysis of present date as 
shown in Figures 3-5,  demonstrate three factors to be highly contributory; 
namely coexistent hypertension (p < 0.001), duration of the disease (p = 0.039) 
and age of the patient  (p = 0.020. Older patients would have harbored the 
disease and hypertension for a longer period of time. Patients with partially or 
poorly treated thyrotoxicosis and hypertension, drift in and out of hospital for 
many years, in some cases for more than thirty years. Gender difference (p = 
0.081) and etiologic diagnosis (p = 0.638) were not significant contributors. 
Patients with heart failure responded rapidly to ATD and anti-failure 
treatment. 
 
 
Figure 3, Heart disease and age of patients 
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Figure 4, Heart disease and total duration of illness 
 
 
Figure 5, Heart disease and hypertension 
 
Conclusion 
Thyrotoxicosis is a common clinical condition. Treatment with 
carbimazole was effective but treatment outcome was marred by a high default 
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rate. Coexisting hypertension and a prolonged period of untreated disease 
exposed patients to a high burden of heart disease. Patient education on the 
disease process, available treatment modalities and timeline and introduction 
of radioablation therapy will mitigate these deficiencies. 
 
Study limitation 
This study is limited by its retrospective nature and the lack of a 
complete dataset. Some of the folders could not be traced and in some folders, 
data was incomplete. 
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